alexa The Combination Of FLT3 Inhibition And Hypomethylation Confers Synergistic Anti-leukemic Activity On FLT3/ITD Positive AML Cell Lines And Primary Cells
ISSN: 2155-9864

Journal of Blood Disorders & Transfusion
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

2nd International Conference on Hematology & Blood Disorders
September 29-October 01, 2014 DoubleTree by Hilton Baltimore-BWI Airport, USA

Heiko Konig
ScientificTracks Abstracts: J Blood Disorders Transf
DOI: 10.4172/2155-9864.S1.006
Effective treatment regimens for elderly FLT3/ITD+ AML patients represent a significant unmet need in the field. Recent data on the effects of the FLT3 tyrosine kinase inhibitor quizartinib on FLT3/ITD+ AML showed promising clinical activity, including in elderly patients. Hypomethylating agents such as decitabine and azacitidine demonstrated clinical benefit in AML, are well tolerated, and are associated with minimal increases in FLT3 ligand, which can represent a potential resistance mechanism to FLT3 inhibitors. In addition, both FLT3 inhibition and hypomethylation therapy are associated with the induction of terminal differentiation of myeloid blasts. Consequently, there is a strong theoretical rationale for combining FLT3 inhibition and hypomethylation for FLT3/ITD+ AML, particularly in the elderly. We therefore utilized proliferation and apoptosis assays to study the antileukemic effects of decitabine, azacitidine and quizartinib, either as single agents or in combination, on AML cell lines and primary cells derived from newly diagnosed and relapsed AML patients. Our studies indicate that i) stroma blunts the effect of all treatments, ii) azacitidine exerts more cytotoxic effects than decitabine, at least from the standpoint of inducing growth inhibition or apoptosis, iii) combined treatment results in synergistic antileukemic effects that are more pronounced in the presence of stroma as compared to the absence of stroma, and iv) a trend towards greater cytotoxicity can be observed when the drugs are administered simultaneously, rather than in a sequential mode. Combined treatment using FLT3 inhibition and hypomethylation therefore may provide a novel therapeutic approach for FLT3/ITD+ AML, particularly for older patients.
Heiko Konig received his MD and Doctorate degrees from the medical schools at the Ludwig Maximilians University Munich and the Philipps University Marburg/ Germany, respectively. He has a long time interest in targeting deregulated signaling pathways and drug resistance in myeloid leukemias and has published several papers in journals such as Blood, Cancer Research and Leukemia. Following his medical training in Germany he joined Dr. Ravi Bhatia?s lab at City of Hope, Duarte/CA, as a Postdoctoral fellow from 2005-2008. From 2008-2011, he underwent residency training in Internal Medicine at the St. Louis University Hospital in St. Louis/MO. He is currently an Assistant Professor of Medicine at the Indiana University Melvin & Bren Simon Cancer Center in Indianapolis, starting in July 2014. He is board certified in Internal Medicine and Medical Oncology.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version